// App-Quantinova.ai

3204 : INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells

Researchers

Presenter

  • Ana Maria Gonzalez

Principal Investigators

  • Mariana L. Manrique

  • Ekaterina Breous

  • David Savitsky

  • Jeremy Waight

  • Randi Gombos

  • Yuqi Liu

  • Shiwen Lin

  • Taha Merghoub

  • Daniel Hirschhorn-Cymerman

  • Gerd Ritter

  • Jedd Wolchok

  • Peggy Scherle

  • Gregory Hollis

  • Reid Huber

  • Marc Van Dijk

  • Robert Stein

  • Nicholas S. Wilson

Medical Centers

  • Agenus Bio, Inc, Lexington, MA

  • Agenus Inc/ -Antibody, Basel, Switzerland

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Ludwig Institute for Cancer Research, Ltd., New York, NY

  • Incyte Corp., Wilmington, DE.

Locations

  • United States

  • Switzerland

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • T-cell receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved